0.1114

37.27% -0.0662

Sangamo Therapeutics Inc (SGMO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$0.1776

Aprire:

$0.1479

Volume 24 ore:

44.56M

Relative Volume:

4.53

Capitalizzazione di mercato:

$46.15M

Reddito:

$39.55M

Utile/perdita netta:

$-122.93M

Rapporto P/E:

-0.2519

EPS:

-0.4423

Flusso di cassa netto:

$-97.31M

1 W Prestazione:

-44.58%

1M Prestazione:

-62.88%

6M Prestazione:

-79.75%

1 anno Prestazione:

-84.53%

Intervallo 1D:

$0.1051

$0.1999

Intervallo di 1 settimana:

$0.1051

$0.217

Portata 52W:

$0.1051

$0.766

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Nome

Sangamo Therapeutics Inc

Settore

Healthcare (1106)

Industria

Biotechnology (615)

Telefono

Indirizzo

Dipendente

Cinguettio

@sangamotx

Prossima data di guadagno

2026-05-11

Ultimi documenti SEC

SGMO's Discussions on Twitter

Compare SGMO vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SGMO Sangamo Therapeutics Inc	0.1114	73.58M	39.55M	-122.93M	-97.31M	-0.4423
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-11-07	Downgrade	Barclays	Overweight → Equal Weight
2024-12-13	Aggiornamento	Truist	Hold → Buy
2024-12-10	Reiterato	H.C. Wainwright	Buy
2023-11-03	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2023-04-28	Downgrade	BofA Securities	Neutral → Underperform
2023-02-27	Aggiornamento	Wedbush	Neutral → Outperform
2023-01-06	Downgrade	BofA Securities	Buy → Neutral
2022-06-13	Ripresa	Wedbush	Neutral
2021-05-04	Iniziato	RBC Capital Mkts	Outperform
2021-01-07	Ripresa	Guggenheim	Neutral
2021-01-06	Iniziato	Stifel	Hold
2020-12-16	Ripresa	H.C. Wainwright	Buy
2020-09-08	Iniziato	BofA Securities	Buy
2020-07-07	Iniziato	SunTrust	Buy
2019-08-26	Iniziato	H.C. Wainwright	Buy
2018-11-14	Downgrade	JP Morgan	Overweight → Neutral
2018-11-09	Downgrade	Guggenheim	Buy → Neutral
2018-10-10	Iniziato	Guggenheim	Buy
2018-06-20	Iniziato	BofA/Merrill	Buy
2017-11-15	Aggiornamento	Piper Jaffray	Neutral → Overweight
2017-06-22	Ripresa	Jefferies	Buy
2016-11-01	Downgrade	Wedbush	Outperform → Neutral
2016-10-19	Downgrade	Piper Jaffray	Overweight → Neutral
2015-12-04	Iniziato	Wells Fargo	Outperform
2015-10-23	Ripresa	Jefferies	Buy
2013-05-03	Iniziato	BioLogic Equity Research	Sell
2011-02-23	Reiterato	JMP Securities	Mkt Outperform
2010-07-29	Reiterato	Wedbush	Outperform
2009-10-19	Iniziato	Brean Murray	Sell
2009-10-07	Reiterato	Leerink Swann	Outperform
2009-08-25	Reiterato	JMP Securities	Mkt Outperform

Mostra tutto

Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie

04:08 AM

Cost of goods sold of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView

04:08 AM

03:35 AM

Sangamo Therapeutics, Inc. Earnings and Revenue – OTC:SGMO - TradingView

03:35 AM

May 04, 2026

Sangamo Stock Jumps Before Nasdaq Exit: Why SGMO Investors Are Watching May 5 - TechStock²

May 04, 2026

SGMO Forecast, Price Target & Analyst Ratings | SANGAMO THERAPEUTICS INC (NASDAQ:SGMO) - ChartMill

May 01, 2026

Apr 30, 2026

MSN Money - MSN

Apr 30, 2026

Sangamo Therapeutics 2025 Executive Compensation, Stock Awards, and Corporate Objectives Overview - Minichart

Apr 30, 2026

Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) - The Manila Times

Apr 30, 2026

SGMO Financials: Income Statement, Balance Sheet & Cash Flow | Sangamo Therapeutics Inc - Stock Titan

Apr 30, 2026

H.C. Wainwright Reaffirms Their Buy Rating on Sangamo Therapeutics (SGMO) - The Globe and Mail

Apr 30, 2026

Apr 29, 2026